PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat population; Phase 1b data demonstrate ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced that the Phase 1 trial of the PLAT-08 study of SC-DARIC33 in Acute ...

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and ...

The last time I spoke about Upstream Bio, Inc. (UPB) it was in a Seeking Alpha article entitled "Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation." With respect to this ...

MIAMI, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Klothea Bio, Inc. (“Klothea Bio”), a clinical-stage biotechnology company developing therapeutics based on their proprietary serum klotho platform, today ...

GRI Bio, Inc. has received a recommendation from the Independent Data Monitoring Committee to continue its Phase 2a study of GRI-0621 for the treatment of idiopathic pulmonary fibrosis (IPF) following ...

Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener Essex ...

The MarketWatch News Department was not involved in the creation of this content. MIAMI, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Klothea Bio, Inc. ("Klothea Bio"), a clinical-stage biotechnology company ...

Belite Bio's lead drug, Tinlarebant, shows promise in rare eye diseases, but pivotal data and regulatory approval remain at least 18 months away in my view. The DRAGON study's interim analysis is ...

The Biology Department values studying abroad as a complement to a liberal arts education and a compelling option for fulfilling the COLL 300 requirement. Students who choose to study abroad gain ...